On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...

New evidence shows GnRH antagonist stimulation outperforms PPOS for oocyte yield in young high-risk IVF patients, supporting ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

GENEVA, Switzerland May 9, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation ...

Kissei Pharmaceutical Co ( ($JP:4547) ) has issued an announcement. Kissei Pharmaceutical has obtained Japanese manufacturing and marketing ...

The world's first IVF baby, Louise Brown born in England in 1978, was conceived from a naturally developing follicle in her mother's ovary. However, as other groups around the world would quickly ...

GENEVA, Switzerland October 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today ...